pharma · Small Cell Lung Cancer · Metastatic castration-resistant prostate cancer (mCRPC)
Amgen
Amgen is a pharma organization headquartered in Thousand Oaks, USA. Primary therapeutic focus areas include Small Cell Lung Cancer, Metastatic castration-resistant prostate cancer (mCRPC), Cardiovascular Disease, Colorec
One Amgen Center Drive, Thousand Oaks, CA 91320, US HQ
1980 Founded
40,212 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- One Amgen Center Drive, Thousand Oaks, CA 91320, US
- Founded
- 1980
- Employees
- 40,212
- Programs
- 96
- Drugs
- 124
- Patents
- 25
Placebo for AMG 145, EVOLOCUMAB
Phase 3 · small molecule · Adults at high risk of cardiovascular events without prior MI or stroke.
Placebo for AMG 145, EVOLOCUMAB for Adults at high risk of cardiovascular events without prior MI or stroke. is a Phase 3 program (small_molecule) at Amgen with 1 ClinicalTrials.gov record(s).
Internal code 20170625
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Amgen
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Adults at high risk of cardiovascular events without prior MI or stroke.
- Status
- active
- Trials
- 1